Use of venovenous ECMO for neonatal and pediatric ECMO: a decade of experience at a tertiary children’s hospital

Carpenter, Jennifer L.; Yu, Yangyang R.; Cass, Darrell L.; Thomas, James A.; Burgman, Cole; Fernandes, Caraciolo J.; Lee, Timothy C.

doi:10.1007/s00383-018-4225-5

Cited by 43 publications

(34 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, surgeons often performed veno-arterial ECMO cannulation via the internal jugular vein and carotid artery or central ECMO cannulation after sternotomy. However, neurologic complications were higher in veno-arterial cannulation than in veno-venous cannulation [1]. Recently, veno-venous ECMO using the DLC has been reported as an efficient tool in aiding pediatric patients with respiratory failure, as in the present case [3,4].…”

Section: Discussionmentioning

confidence: 67%

Percutaneous bicaval dual lumen cannula for extracorporeal life support

et al. 2020

View full text Add to dashboard Cite

Percutaneous bicaval dual lumen cannula for extracorporeal life support Veno-venous extracorporeal membrane oxygenation (ECMO) is a useful mechanical device for pediatric patients with severe respiratory failure. Conventional veno-venous ECMO using double cannulation, however, is not feasible due to size limitations in pediatric patients who have small femoral vessels. Recently, percutaneous bicaval dual-lumen cannula can be inserted using single cannulation via the right internal jugular vein. Herein, we report the case of a pediatric patient with severe respiratory failure who was weaned off the ECMO successfully after treatment with bicaval dual-lumen cannulation for 5 days despite the small body size and immunocompromised condition due to chemotherapy for hemophagocytic lymphohistiocytosis.

show abstract

Section: Discussionmentioning

confidence: 67%

Percutaneous bicaval dual lumen cannula for extracorporeal life support

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The length of this ECMO run made transport of this immunocompromised and pancytopenic patient necessary. Notably, ECMO circuits are increasingly portable, 22,23 and this is likely to allow for greater access to a broader range of hospital services for critically ill pediatric oncology patients in the coming years. Also in this case significant complications of therapy such as pancytopenia, profound immunosuppression, and febrile neutropenia/sepsis occurred during the ECMO run.…”

Section: Discussionmentioning

confidence: 99%

Continuous infusion chemotherapy, radiotherapy, and FDG‐PET are feasible during extracorporeal membrane oxygenation

Rotz

Almeida

Koyfman

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Extracorporeal membrane oxygenation (ECMO) may be used in extreme circumstances for patients with a mediastinal mass and respiratory failure. We report on a young man with primary mediastinal B‐cell lymphoma invading into the trachea, requiring a 40‐day ECMO run who underwent fluorodeoxyglucose positron emission tomography (FDG‐PET) imaging and treatment with concurrent mediastinal irradiation and continuous infusion chemotherapy while on this life‐saving technology. This case illustrates that oncology patients may be managed by multidisciplinary teams for extended periods in extraordinary circumstances using multimodality therapies. Additionally, to our knowledge this is the first case to demonstrate the feasibility of FDG‐PET imaging while on ECMO.

show abstract

“…The survival rate of VV-ECMO was 66%. Carpenter et al 7 jointly evaluated the pediatric and neonatal patients in their study, and VV-ECMO was performed for 83 patients, and 49 patients (59%) survived. : partial pressure of CO 2 in the arterial blood (mm Hg); paO 2 : partial pressure of oxygen in the arterial blood, platelet count (K/µl), HCO 3 : bicarbonate (mmol/L), lactate (mmol/L), WBC: white blood cell count (K/µl), hemoglobin (g/dl), platelet count (K/µl); urea (mg/dl), creatinine (mg/dl), albumin (g/dl), chloride (meq/L), LDH: lactate dehydrogenase (U/L)…”

Section: Discussionmentioning

confidence: 99%

Clinical and laboratory predictors of survival for pediatric patients on non-postcardiotomy extracorporeal membrane oxygenation (ECMO)

Şık¹,

Demirbuğa²,

Temur³

et al. 2020

Turk J Pediatr

View full text Add to dashboard Cite

Extracorporeal membrane oxygenation (ECMO) is used in pediatric patients with severe cardiopulmonary failure who do not respond to conventional therapy; only a few studies have been conducted in Turkey. We present the experience of pediatric ECMO with the aim of showing factors affecting mortality. We retrospectively reviewed our ECMO database to identify patients who received ECMO from October 2015 to March 2018. Our population comprised 30 pediatric patients. The mean patient age was 41.31±53.35 months and 17 (56.7%) patients were male. The median duration of ECMO support was 8.9 (6.6-10.8) days. The rates of successful ECMO weaning and survival to discharge were 70.0% (n=21) and 66.7% (n=20), respectively. Indications for ECMO were respiratory failure (40.0%), cardiac failure (33.3%), and sepsis (26.7%). We found that pre-cannulation values of pH (p=0.034), leukocytes (p=0.029), C-reactive protein (p=0.045), creatinine (p=0.047), chloride (p=0.001) and post-cannulation pH (p=0.0001), bicarbonate (p=0.014), lactate (p=0.002), chloride (p=0.0001) were associated with mortality. The results showed that preexisting sepsis and renal conditions contributed to poor outcomes. Indications, ECMO onset time, and pre-and post-cannulation laboratory values such as leukocytes, CRP, creatinine, bicarbonate, lactate, and chloride are factors that affect outcomes.

show abstract

Use of venovenous ECMO for neonatal and pediatric ECMO: a decade of experience at a tertiary children’s hospital

Abstract: II.

Cited by 43 publications

References 18 publications

Percutaneous bicaval dual lumen cannula for extracorporeal life support

Percutaneous bicaval dual lumen cannula for extracorporeal life support

Continuous infusion chemotherapy, radiotherapy, and FDG‐PET are feasible during extracorporeal membrane oxygenation

Clinical and laboratory predictors of survival for pediatric patients on non-postcardiotomy extracorporeal membrane oxygenation (ECMO)

Contact Info

Product

Resources

About